Print Page | Close Window

Cytokinetics, Inc. (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and other medical conditions.  Cytokinetics currently has three compounds in clinical development: omecamtiv mecarbil in Phase II for acute and chronic heart failure... Details >>

Link to Annual Report & Stockholder Meeting Materials and Information

Stock Quote
CYTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.05 (0.71%)
Market Cap$270,519,065
Shares Outstanding38,756,313
Data as of 10/08/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsDetails >>
07/29/15Cytokinetics, Inc. Reports Second Quarter 2015 Financial ResultsPrinter Friendly Version
07/15/15Cytokinetics to Announce Second Quarter Results on July 29, 2015Printer Friendly Version
07/14/15Cytokinetics Announces Start of Phase 3 Clinical Trial of Tirasemtiv in Patients With ALSPrinter Friendly Version
07/14/15Cytokinetics and the ALS Association Announce Awarding of Grant for Phase 3 Clinical Trial and Biomarker Research CollaborationPrinter Friendly Version
Upcoming EventsDetails >>
There are currently no events scheduled.
Featured ReportDetails >>
Download Documentation 2014 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.